Patients with BRCA1-mutant breast cancer and high EZH2 expression showed an improved therapeutic response and less frequent disease recurrence after treatment with intensified platinum-based chemotherapy, compared to standard chemotherapy [14]. Here, EZH2 is linked to breast carcinoma.